Technical Analysis for NLNK - NewLink Genetics Corporation

Grade Last Price % Change Price Change
grade F 1.88 -10.05% -0.21
NLNK closed down 10.05 percent on Friday, November 16, 2018, on 1.69 times normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical NLNK trend table...

Date Alert Name Type % Chg
Nov 16 Fell Below 20 DMA Bearish 0.00%
Nov 16 New 52 Week Low Weakness 0.00%
Nov 16 Oversold Stochastic Weakness 0.00%
Nov 15 Slingshot Bearish Bearish Swing Setup -10.05%
Nov 15 Crossed Above 20 DMA Bullish -10.05%
Nov 15 Oversold Stochastic Weakness -10.05%
Nov 14 20 DMA Resistance Bearish 1.08%
Nov 14 New 52 Week Closing Low Bearish 1.08%
Nov 14 New 52 Week Low Weakness 1.08%
Nov 14 Stochastic Reached Oversold Weakness 1.08%

Older signals for NLNK ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
NewLink Genetics Corporation, a biopharmaceutical company, through its subsidiary, BioProtection Systems Corporation, focuses on discovering, developing, and commercializing immunotherapeutic products to enhance cancer treatment options for patients and physicians. Its portfolio includes biologic and small-molecule immunotherapy product candidates based on proprietary HyperAcute immunotherapy technology for the treatment of various oncology indications. The company's lead product candidate, HyperAcute Pancreas cancer immunotherapy, is being studied in two Phase III clinical trials in surgically-resected pancreatic cancer patients. It is also developing HyperAcute Lung, which is being studied in a multi-center randomized, controlled Phase IIB/III clinical trials for non-small cell lung cancer; HyperAcute Melanoma that is in Phase II clinical trials for the treatment of melanoma; and a HyperAcute Renal cell cancer immunotherapy, as well as HyperAcute prostate and HyperAcute breast product candidates. In addition, the company is developing Indoximod, a small-molecule, orally bioavailable product candidate, which is being evaluated for the treatment of metastatic solid tumors in two Phase IB/II clinical trials; Provenge Indoximod that is in Phase II clinical trials for the treatment of prostate cancer; Docetaxel Indoximod, which is in Phase II clinical trials for the treatment of metastatic breast cancer; HyperAcute immunotherapy plus Indoximod that is in Phase IIB clinical trials; and NLG-919 IDO Pathway Inhibitor Candidate, which is in Phase I clinical trials for the treatment of metastatic solid tumors. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.
Is NLNK a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 10.41
52 Week Low 1.83
Average Volume 487,851
200-Day Moving Average 4.4758
50-Day Moving Average 2.2324
20-Day Moving Average 2.032
10-Day Moving Average 2.04
Average True Range 0.1837
ADX 19.07
+DI 17.9595
-DI 18.0956
Chandelier Exit (Long, 3 ATRs ) 1.9289
Chandelier Exit (Short, 3 ATRs ) 2.3811
Upper Bollinger Band 2.2557
Lower Bollinger Band 1.8083
Percent B (%b) 0.16
BandWidth 22.017717
MACD Line -0.0839
MACD Signal Line -0.0856
MACD Histogram 0.0017
Fundamentals Value
Market Cap 55.31 Million
Num Shares 29.4 Million
EPS -2.29
Price-to-Earnings (P/E) Ratio -0.82
Price-to-Sales 6.79
Price-to-Book 2.71
PEG Ratio -0.21
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.32
Resistance 3 (R3) 2.35 2.23 2.24
Resistance 2 (R2) 2.23 2.12 2.22 2.22
Resistance 1 (R1) 2.06 2.05 2.00 2.03 2.19
Pivot Point 1.94 1.94 1.92 1.93 1.94
Support 1 (S1) 1.77 1.83 1.71 1.74 1.57
Support 2 (S2) 1.65 1.76 1.64 1.54
Support 3 (S3) 1.48 1.65 1.52
Support 4 (S4) 1.45